ArticleJournal of cellular and molecular medicine2026
Adipose Mesenchymal Stem Cells Secreted Exosomal miR-26a-5p Ameliorate Renal Fibrosis via Inhibiting Glycolysis and Ferroptosis in Renal Interstitial Fibrosis.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Renal fibrosis, a defining feature of chronic kidney disease, involves a metabolic shift toward aerobic glycolysis and is frequently accompanied by ferroptosis, a form of iron-dependent cell death. This study investigated the therapeutic potential of adipose mesenchymal stem cell-derived exosomes (AMSC-exo) in renal fibrosis. Using a unilateral ureteral obstruction (UUO) mouse model and hypoxia-treated HK-2 cells, we assessed fibrosis, glycolysis, mitochondrial morphology, and ferroptosis. miRNA sequencing, dual-luciferase reporter assays, and transcriptome sequencing were performed to identify key exosomal miRNAs and downstream pathways. AMSC-exo significantly attenuated UUO-induced fibrosis and suppressed glycolysis and ferroptosis in tubular epithelial cells. miR-26a-5p was highly enriched in AMSC-exo and downregulated 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (Pfkfb3), a key regulator of glycolysis and ferroptosis. Knockdown of miR-26a-5p markedly weakened the renoprotective effects of AMSC-exo, whereas Pfkfb3 inhibition reversed the effects induced by miR-26a-5p deficiency. These findings indicate that AMSC-exo alleviate renal fibrosis by delivering miR-26a-5p to suppress Pfkfb3, thereby inhibiting glycolytic reprogramming and ferroptosis, and suggest the miR-26a-5p/Pfkfb3 axis as a potential therapeutic target for renal fibrosis.
Indexed as
Identifiers
42885940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.